Partner
WASHINGTON, DC - The U.S. District Court for the District of Delaware ruled on May 29, 2012, in favor of Finnegan client Pronova BioPharma Norge AS in its patent litigations against Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. regarding their efforts to obtain FDA approval to market generic copies of Lovaza®. The District Court held that the asserted claims of U.S. Patent No. 5,656,667 and U.S. Patent No. 5,502,077 are valid and enforceable, thus maintaining patent protection for Lovaza® in the United States until at least April of 2017. The District Court also held that the proposed generic products infringe these patent claims. Lovaza® is prescribed as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, with over $900 million in U.S. sales in 2011. Pronova markets this product in the U.S. with GlaxoSmithKline, which was not a party to these litigations.
Pronova previously filed a similar action against Apotex Corp. and Apotex Inc., which the parties settled in March of 2011.
With more than 375 intellectual property lawyers, Finnegan is one of the largest IP law firms in the world. From offices in Washington, DC; Atlanta, Georgia; Cambridge, Massachusetts; Palo Alto, California; Reston, Virginia; Brussels, Belgium; Shanghai, China; Taipei, Taiwan; and Tokyo, Japan, the firm practices all aspects of patent, trademark, copyright, and trade secret law, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com. ###
Media Mention
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.